In MM patients randomized to G-CSF plus plerixafor, 71.6% of the patients achieved the primary study endpoint (collection of at least 6 × 106/kg CD34+ cells with less or equal to two aphereses) compared to only 34.4% of patients receiving G-CSF and placebo.41 Similarly, 59% of NHL patients achieved the primary study endpoint (collection of at least 5 × 106/kg CD34+ cells with less or equal to four aphereses) compared to only 19.6% of patients mobilized with G-CSF plus placebo.42 Plerixafor-mobilized PBSCs did show rapid and sustained engraftment after high-dose therapy in both studies. This evidence concerns the gene CD34 and Miyoshi myopathy.